RCUS – arcus biosciences, inc. (US:NASDAQ)
Stock Stats
News
1/12
05:02 pm
rcus
Medium
Arcus Biosciences (NYSE:RCUS) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating.
1/10
01:07 am
rcus
Low
Arcus Biosciences (NYSE:RCUS) was downgraded by analysts at Wall Street
1/8
07:09 am
rcus
Medium
Arcus Biosciences (NYSE:RCUS) was given a new $20.00 price target on by analysts at Morgan Stanley.
1/7
04:23 pm
rcus
Medium
Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs [Yahoo! Finance]
1/7
04:05 pm
rcus
Medium
Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs
8/6/2025
04:05 pm
rcus
-2.2%
BEAT
5/6/2025
04:05 pm
rcus
-1.4%
MISS
2/25/2025
04:05 pm
rcus
-1.0%
BEAT
2/25/2025
04:05 pm
rcus
-1.0%
BEAT
1/13
12:23 pm
Upgrades
Neutral
Buy
Goldman Sachs
Low
1.7%
1/13
12:23 pm
Upgrades
Neutral
Buy
Goldman Sachs
Low
1.7%
1/13
12:23 pm
Upgrades
Neutral
Buy
Goldman Sachs
Low
1.7%
1/12
04:30 pm
Upgrades
NEUTRAL
BUY
GOLDMAN SACHS
Medium
4.6%
1/12
04:30 pm
Upgrades
NEUTRAL
BUY
GOLDMAN SACHS
Medium
4.6%
1/9
04:26 pm
rcus
Low
Form 4 Arcus Biosciences, Inc. For: Jan 08 Filed by: ROSEN TERRY J
1/8
01:28 pm
rcus
Neutral
Form SCHEDULE 13G/A Arcus Biosciences, Inc. Filed by: BlackRock, Inc.
1/7
04:16 pm
rcus
Medium
Form 4 Arcus Biosciences, Inc. For: Jan 05 Filed by: Jaen Juan C.
1/5
04:58 pm
rcus
Low
Form 144 Arcus Biosciences, Inc. Filed by: Jaen Juan C.
1/2
04:19 pm
rcus
Medium
Form 4 Arcus Biosciences, Inc. For: Dec 31 Filed by: Goeltz II Robert C.
Show more
Top News Gainers
9/26 Arcus Biosciences Inc (NYSE: RCUS) is now covered by analysts at Mizuho. They set a "buy" rating on the stock. 15.6%
2/18 Arcus Biosciences Inc (NYSE: RCUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $13.00 price target on the stock. 12.7%
8/8 Arcus Biosciences Inc (NYSE: RCUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 11.0%
3/4 Arcus Biosciences Inc (NYSE: RCUS) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $24.00 price target on the stock. 7.7%
6/11 Arcus Biosciences to Provide a Mid-Year Update on Clinical and Preclinical Programs 6.4%
11/12 Arcus Biosciences Inc (NYSE: RCUS) is now covered by analysts at SunTrust Banks, Inc.. They set a "buy" rating on the stock. 5.4%
4/9 Arcus Biosciences Announces New Employment Inducement Grants 5.3%
12/18 Arcus Biosciences, in Collaboration with Genentech, Announces Two Randomized Clinical Studies to Advance AB928, a Dual Adenosine Receptor Antagonist, into Novel Combinations for Colorectal and Pancreatic Cancers 4.9%
10/30 Form 4 Arcus Biosciences, Inc. For: Oct 28 Filed by: Ribas Antoni 4.5%
7/4 Arcus Biosciences Inc (NYSE: RCUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.25 price target on the stock. 4.4%
Top News Decliners
3/14 Arcus Biosciences Inc (NYSE: RCUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock. -24.3%
2/25 Arcus Biosciences Inc (NYSE: RCUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.5%
11/25 Form 8-K/A Arcus Biosciences, Inc. For: Sep 10 -8.8%
4/7 Form 8-K Arcus Biosciences, Inc. For: Apr 07 -7.6%
11/7 Arcus Biosciences Inc (NYSE: RCUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.3%
10/4 Form 3 Arcus Biosciences, Inc. For: Oct 01 Filed by: Barker Jason -6.7%
4/16 Arcus stock jumps on Bloomberg News report that Gilead may take a stake [MarketWatch] -6.3%
3/3 Arcus Biosciences Inc (NYSE: RCUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock. -5.3%
2/22 3 Biotech Stocks That Soared This Week: Are They Buys? [The Motley Fool] -5.1%
2/26 Arcus Biosciences Inc (NYSE: RCUS) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $22.00 price target on the stock. -4.8%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3